Document is current
Any future updates will be listed below
-
Authors
Hägerstrand, Daniel https://orcid.org/0000-0001-7270-0776
Oder, Blaž https://orcid.org/0000-0001-7984-3104
Cortese, Diego
Qu, Ying
Binzer-Panchal, Amrei https://orcid.org/0000-0002-0472-0609
Österholm, Cecilia
Del Peso Santos, Teresa
Rabbani, Leily
Asl, Hassan Foroughi
Skaftason, Aron
Ljungström, Viktor
Lundholm, August
Koutroumani, Maria
Haider, Zahra
Jylhä, Cecilia
Mollstedt, John
Mansouri, Larry
Plevova, Karla
Agathangelidis, Andreas https://orcid.org/0000-0002-8467-7945
Scarfò, Lydia https://orcid.org/0000-0002-0844-0989
Armand, Marine https://orcid.org/0000-0001-8906-3128
Muggen, Alice F.
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Shanafelt, Tait
Rossi, Davide
Orre, Lukas M. https://orcid.org/0000-0002-0384-1003
Pospisilova, Sarka https://orcid.org/0000-0001-7136-2680
Barylyuk, Konstantin https://orcid.org/0000-0002-3580-0345
Davi, Frederic
Vesterlund, Mattias https://orcid.org/0000-0001-9471-6592
Langerak, Anton W. https://orcid.org/0000-0002-2078-3220
Lehtiö, Janne https://orcid.org/0000-0002-8100-9562
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Stamatopoulos, Kostas https://orcid.org/0000-0001-8529-640X
Sutton, Lesley-Ann
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
- License Information
-
More Information
Article History
Received: 28 March 2024
Revised: 7 August 2024
Accepted: 12 August 2024
First Online: 11 September 2024
Competing interests
: NEK advisory board: AbbVie, AstraZeneca, BeiGene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics/Celgene, ONCOtracker, Pharmacyclics, and Targeted Oncology; research funding: AbbVie, Acerta Pharma/AstraZeneca, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. AWL honoraria: Janssen and Roche. PG honoraria/advisory board: AbbVie, Acerta Pharma/AstraZeneca, Adaptive, ArQule/MSD, BeiGene, Juno Therapeutics/Celgene, Gilead, Janssen, Loxo Oncology/Lilly, and Sunesis; research funding: AbbVie, Gilead, Janssen, Novartis, and Sunesis. KS honoraria: Janssen, Abbvie, and AstraZeneca; research funding: Janssen, Gilead Sciences, and AbbVie. LAS honoraria: AbbVie and Janssen. RR honoraria: AbbVie, AstraZeneca, Janssen, Illumina, and Roche. The other authors declare no competing interests.
